26th week of 2010 patent applcation highlights part 43 |
Patent application number | Title | Published |
20100166660 | METHODS OF MODELING MIGRAINE PAIN AND IDENTIFYING CANDIDATE COMPOUNDS FOR THE TREATMENT OF MIGRAINE - The present invention features animal models of migraine pain that can be used in a variety of ways, e.g., to identify compounds that reduce migraine pain or other migraine symptoms, to investigate behavioral changes correlated with the development and maintenance of a migraine-like state, and to better understand the mechanisms that underlie migraine pain. | 2010-07-01 |
20100166661 | siRNA COMPOSITIONS AND METHODS FOR POTENTLY INHIBITING VIRAL INFECTION - No antiviral regimen has been consistently successful in treating H5N1 virus infection. We demonstrate that a group of highly effective siRNAs targeting different H5N1 viral genes shares a unique motif, GGAGU/ACUCC. We further demonstrate that the effectiveness of siRNAs containing this motif is not sequence specific. The results suggested that the structure of the unique motif is critical in determining the potency of siRNA-mediated protective effects against viral infection and this potent in vivo protection is associated with early productions of β-defensin and IL-6 induced by the motif. Provided are methods and prophylactic and therapeutic agents useful against other viral infections in addition to the H5N1 influenza virus. | 2010-07-01 |
20100166662 | MAGNETIC RESONANCE IMAGING METHOD USING VANADYL-BASED CONTRAST AGENTS - A new, clinically applicable magnetic resonance imaging (MRI) method has been developed for in vivo imaging of a population of cells in a subject based on a class of paramagnetic divalent vanadyl-based contrast agents. The method includes administering to a subject a V | 2010-07-01 |
20100166663 | PROBE FOR A HAIR CELL, AND LABELLING METHOD FOR A HAIR CELL USING THE PROBE FOR A HAIR CELL - Provided are a novel probe for a hair cell for clearly identifying various conditions of a hair cell, and a labelling method for a hair cell using the probe for a hair cell, more particularly, a probe for a hair cell containing, as an active agent, at least one kind selected from staining compounds represented by one of the general formulae (I) and (II), and a labelling method for a hair cell using the probe for a hair cell. | 2010-07-01 |
20100166664 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING - Compositions of nanoparticles functionalized with at least one zwitterionic moiety, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprises a core, having a core surface essentially free of silica, and a shell attached to the core surface. The shell comprises at least one silane-functionalized zwitterionic moiety. | 2010-07-01 |
20100166665 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING - Compositions of nanoparticles functionalized with at least one zwitterionic moiety, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprises a core, having a core surface essentially free of silica, and a shell attached to the core surface. The shell comprises at least one silane-functionalized zwitterionic moiety. | 2010-07-01 |
20100166666 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING - Compositions of nanoparticles functionalized with at least one zwitterionic moiety, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprises a core, having a core surface essentially free of silica, and a shell attached to the core surface. The shell comprises at least one silane-functionalized zwitterionic moiety. | 2010-07-01 |
20100166667 | MAGNETIC RESONANCE IMAGING - A method of determining the amount of intracellular manganese in the myocardium of an individual pre-administered with a manganese contrast agent, or a pharmaceutically acceptable salt thereof, comprising subjecting said individual to a MRI procedure to assess the signal intensity (SI) of images, or more preferably the longitudinal relaxation rate, R | 2010-07-01 |
20100166668 | CT NEGATIVE CONTRAST MEDIUM OF AQUEOUS MATRIX FOR DIGESTIVE TRACT AND THE PREPARATION METHOD THEREOF - An aqueous negative contrast agent for CT imaging of the gastrointestinal tract and the preparation method thereof. The agent is used in biological and pharmaceutical field. Its components and the weight percent are: hydrogel matrix 0.01-1%, micro-/nano-particles of the materials with low densities 5-50%, stabilization agents 0.1-5%, the rest is deionized water. The preparation method is: stabilization agents are added into the hydrogel matrix made of natural or synthetic hydrophilic polymers, then micro-/nano-particles of the materials with low CT densities are added or prepared, and uniformly dispersed in the hydrogel matrix. The CT density of the resulted aqueous negative contrast agent for CT imaging of the gastrointestinal tract is −30HU to −500HU. It can decrease the CT density inside the intestine lumen to lower than −30HU. The intestine wall can be depicted clearly and the CT signals intensities inside lumen are uniform. It is feasible for 3D images processing such as virtual endoscopy reconstruction with the negative contrast agent. The agent is safe, stable and nontoxic. It will not lead to diarrhea after administration. It is of great significance for the improved sensitivity and specificity of CT diagnosis for the diseases on the intestinal wall and lumen. | 2010-07-01 |
20100166669 | METHODS OF IMAGING INFLAMMATION IN PANCREATIC ISLETS - Described are non-invasive methods for imaging pancreatic inflammation in living mammals using Magnetic Nanoparticle Probes (MNPs). | 2010-07-01 |
20100166670 | USE OF BOSWELLIC ACID AND ITS DERIVATIVES FOR INHIBITING NORMAL AND INCREASED LEUCOCYTIC ELASTASE OR PLASMIN ACTIVITY - The invention concerns the use of pure boswellic acid, a physiologically acceptable salt, a derivative, a salt of the derivative or a plant preparation containing boswellic acid for preventing and/or combatting diseases which are caused by increased leucocytic elastase or plasmin activity or can be treated by the inhibition of, normal leucocytic elastase or plasmin activity, in human or veterinary medicine. | 2010-07-01 |
20100166671 | ORGANIC COMPOUNDS - Medicaments comprising (A) an antimuscarinic agent, (B) a beta-2 adrenoreceptor agonist and (C) a corticosteroid for the treatment of inflammatory or obstructive airways diseases. | 2010-07-01 |
20100166672 | FOAM-FORMING COMPOSITION - The present invention relates to a novel foam-forming composition suitable for rectal administration of locally-acting pharmaceutically active ingredients, and the product adapted to administer said foam-forming composition. Also, the present invention relates to a method for its preparation. According to the present invention a foam-forming composition is provided which exhibits a high expansion ratio and at the same time conferring optimal appearance of the formed foam to allow sufficient contact time of the active to the target site in the intestine in order to obtain optimal local effect. The composition according to the present inventions provides superior properties for the treatment of rectal diseases. | 2010-07-01 |
20100166673 | AEROSOLIZED FLUOROQUINOLONES AND USES THEREOF - Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described. | 2010-07-01 |
20100166674 | TRANSDERMAL DELIVERY RATE CONTROL USING AMORPHOUS PHARMACEUTICAL COMPOSITIONS - A pharmaceutical composition for transdermal delivery comprising
| 2010-07-01 |
20100166675 | Pharmaceutical Composition for the Treatment of Type 1-Diabetes - A composition for the prevention or treatment of type I diabetes in a subject, said composition comprising a GABAergic and incretin exemplified by GABA and GLP-1/Ex4. These are optionally provided together in a single composition to promote beta-cell regeneration prevent beta-cell apoptosis and control autoimmunity for the prevention and treatment of T1D in mammals. | 2010-07-01 |
20100166676 | RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS - RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example. | 2010-07-01 |
20100166677 | Use of Tiliacora Triandra in Cosmetics and Compositions Thereof - The present disclosure relates to compositions and methods for treating, preventing and improving the condition and aesthetic appearance of skin, particularly, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, where the compositions include natural plant constituents which increase expression levels genes, collagen replacement and retention, and cell proliferation of epidermis and dermis associated with the dermatological signs of aging. The compositions of the invention are topically applied to the skin, or are delivered by directed means to a site in need thereof, once daily in an amount effective in improving the condition and aesthetic appearance of skin. | 2010-07-01 |
20100166678 | NONCARIOUS MATERIAL AND ANTICARIOUS AGENT CONTAINING RARE SUGAR - Object: To provide a composition for preventing periodontal diseases (prophylactic agent of periodontal diseases), the composition having an excellent cariostatic property, being safe and stable for prolonged use and having less effects on flavor. | 2010-07-01 |
20100166679 | SWEETNER AND USE - Sweeteners on the basis of a simultaneously transglucosylated sweet glycoside mixture of | 2010-07-01 |
20100166680 | METHOD FOR PRODUCTION OF BIOCOMPATIBLE NANOPARTICLES CONTAINING DENTAL ADHESIVE - A method of synthesizing hydroxyapatite nanorods, having high purity, high crystallinity and high aspect ratio is disclosed here. In one embodiment, high crystalline hydroxyapatite nanorods with relatively stoichiometric structure are prepared via hydrothermal method at 200° C. and under moderate acidic conditions. The synthesized hydroxyapatite nanorods have a diameter of 30-95 nm, a length of 850-1400 nm with an average aspect ratio of 24, degree of crystallinity of 73% and stoichiometry ratio of 1.69. Further it discloses the use of HAp in dental adhesive. The dental adhesive comprising synthesized HAp shows improved diametral tensile strength and high microshear bond strength. Energy dispersive X-ray mapping confirmed the uniform distribution of nanorods in the adhesive matrix. The synthesized hydroxyapatite nanorods have high colloidal stability in the dental adhesive solution. The nanorods are well dispersed and protected from aggregation by their high surface charges confirmed by zeta potential measurement. | 2010-07-01 |
20100166681 | Anhydrous Multiphase Gel System - An anhydrous multiphase gel system consisting of an outer lipid matrix and an inner phase gelled by means of a polymer is described, which can be obtained by a) Melting the lipid phase with the formation of a liquid lipid phase, b) Mixing and homogenizing polymers or polymer blends capable of swelling with the formation of a polymer phase to be dispersed, c) Combining the polymer phase with the liquid lipid phase and homogenizing the phases, and d) Cold stirring the phase mixture until a solid gel-like mixed structure of the entire system is formed. The anhydrous multiphase gel system is particularly suitable for taking up difficultly soluble active substances in high concentration and for providing topical and transdermal applications. The described system is called an EDRS, “Entrapped Drug Reservoir System”. | 2010-07-01 |
20100166682 | CHELATED MINERAL WATER - A composition comprising mineral water and a chelating agent present in an amount sufficient to maintain all of the minerals in the water in solution. The mineral water is preferably obtained from Mount Clemens, Mich., US, and is preferably chelated with an ammonium and/or a sodium salt of an acid selected from the group consisting of ethylenediaminetetraacetic acid, nitrilotetraacetic acid, β-alaninediacetic acid, ethylenediaminosuccinic acid, aminotrimethylenephosphoric acid, serinediaacetic acid, asparaginediacetic acid, methylgylcinediacetic acid and mixtures thereof. The resultant chelated mineral water may be combined with a cosmetically acceptable skin-conditioning agent and a cosmetically acceptable topical carrier, thereby resulting in a cosmetic composition that will confer beneficial effects on the skin, e.g., softening, hydrating and healing effects. | 2010-07-01 |
20100166683 | COMPOSITION OF EXTERNAL PREPARATION FOR UV-PROTECTION COMPRISING REHMANNIA GLUTINOSA EXTRACTS - The present invention relates to a composition for external preparation for UV protection comprising an extract of | 2010-07-01 |
20100166684 | WATER-IN-OIL TYPE EMULSIFIED COSMETIC - There is provided a novel water-in-oil type emulsified cosmetic comprising a diester of neopentylglycol with isononanoic acid. Said cosmetic exhibits not only the refreshed feeling on use without unfavorable stickiness after application, but also proper oily feeling. There are obtained good affinity to the skin, little occurrence of creasing and/or make-up deterioration, no oily sheen upon the elapse of long periods of time after application, and little irritation to the skin and excellent safety to the skin. In addition, the present cosmetic is able to be removed with commercially available cleansing agents. Moreover, the dispersibility of pigments as well as the storage stability is excellent. | 2010-07-01 |
20100166685 | NOVEL BLOCK POLYMERS, COMPOSITIONS COMPRISING THEM, AND TREATMENT METHODS - The present disclosure relates to novel block polymers comprising particular silicone monomers and monomers of formula: | 2010-07-01 |
20100166686 | Water Soluble Thickener And Cosmetic Preparation Containing Same - The invention is a water-soluble thickener made of a copolymer that is obtained by copolymerizing 2-acrylamido-2-methylpropanesulfonic acid or its salt, hydroxyethylacrylamide, and a crosslinking monomer, or that is made of a copolymer that is obtained by further neutralizing said copolymer that has been obtained using an alkaline agent. It also provides a cosmetic in which this water-soluble thickener has been blended. | 2010-07-01 |
20100166687 | COSMETIC LIGHT PROTECTION AGENT - The invention relates to a cosmetic light-protective agent for wavelengths of from 250 to 1400 nm, containing at least methylene bis-benzotriazolyl tetramethylbutylphenol as UVA filter; at least one UVB filter; sea buckthorn oil with a refractive index of from 1.4 to 1.59 and a solid with a d | 2010-07-01 |
20100166688 | PROCESS FOR LIGHTENING KERATIN MATERIALS USING AN EMULSION COMPRISING AN ALKALINE AGENT AND AN OXIDIZING COMPOSITION - The present disclosure therefore relates to a method for lightening keratin materials, in which the following are used: (a) a direct emulsion (A) comprising at least one fatty substance in an amount greater than 25% by weight, such as greater than 50%, at least one surfactant; at least one alkaline agent and an amount of water greater than 5% by weight, of the total weight of the emulsion, (b) a composition (B) comprising at least one oxidizing agent. It also relates to a multi-compartment device comprising, in one compartment, an emulsion (A), in another compartment a composition (B) comprising at least one oxidizing agent. | 2010-07-01 |
20100166689 | Compositions and Methods for Treating Hyperpigmentation - This invention provides compositions and methods for reducing hyperpigmentation. In preferred embodiments, the compositions are topical compositions that contain kojic acid and a carrier molecule for enhancing the transdermal penetration of kojic acid. This invention also provides kits for treating hyperpigmentation. | 2010-07-01 |
20100166690 | Composition for Correcting Scar of Skin - The present invention provides a composition for correcting scar of skin which corrects a scar of skin such as a mark of skin injury, which achieves an excellent effect of correcting a scar of skin with a good covering ability and an ease in applying the composition repeatedly or another thereover and has a good feeling in use as well as an excellent long-lasting effect in makeup. The composition comprises (a) 30 to 50% by mass of titanium oxide and (b) 2 to 20% by mass of coating agents including acrylic-silicone graft copolymer and siliconated polysaccharide compound. | 2010-07-01 |
20100166691 | Polyamide-Polyether Block Copolymer - Copolymers having linked internal polyether blocks and internal polyamide blocks have advantageous physical properties and solvent-gelling abilities. The copolymer may be prepared from a reaction mixture that contains 1,4-cyclohexane dicarboxylic acid (CHDA) and poly(alkyleneoxy)diamine (PAODA). Optionally, the reaction mixture contains no monofunctional compound reactive with either amine or carboxylic acid groups, however some of this monofunctional compound may be present. Dimer diamine and/or dimer acid may be present in the reaction mixture. A copolymer may also be prepared from a reaction mixture containing dimer acid and at least two diamine compound(s) including PAODA and short-chain aliphatic diamine having 2-6 carbons (SDA), wherein: a) the reaction mixture comprises x grams of PAODA and y grams of SDA, and x/(x+y) is 0.8-0.98; b) the reaction mixture weighs z grams, and x/z is at least 0.25; and c) the reaction mixture contains either no co-diacid, or comprises a small amount of co-diacid, wherein, if the reaction mixture comprises a small amount of co-diacid, then acid equivalents from co-diacid contribute less than 25% of the total acid equivalents present in the reaction mixture. | 2010-07-01 |
20100166692 | METHOD FOR TREATING DAMAGED HAIR IN CONJUNCTION WITH THE RELAXING PROCESS - A method of treating one or more damaged hair shafts, each hair shaft including a cuticle layer and a cortex enclosed in the cuticle layer is disclosed. The method comprises: selecting one or more polymers that can penetrate the hair shafts with a pore size of about 5 angstroms to about 5000 angstroms; and treating the hair shafts by applying an effective amount of a composition containing said anionic polymers to said hair shafts. | 2010-07-01 |
20100166693 | DETERGENT COSMETIC COMPOSITION COMPRISING AT LEAST FOUR SURFACTANTS, AT LEAST ONE CATIONIC POLYMER AND AT LEAST ONE ZINC SALT - The present disclosure relates to a cosmetic composition for keratin fibers, for example, human keratin fibers such as hair, comprising: at least one anionic surfactant (A) comprising, in its structure, at least one group chosen from sulphate, sulphonate, and phosphate groups; at least one carboxylic anionic surfactant (B) other than the at least one anionic surfactant (A); at least one surfactant (C) chosen from amphoteric and zwitterionic surfactants; at least one alkyl(poly)glycoside non-ionic surfactant (D); at least one cationic polymer (E); at least one zinc salt (F); and optionally at least one UV-screening agent (G); and further wherein the weight ratio of the total amount of the surfactants (A), (B), (C), and (D) to the amount of zinc element of the at least one zinc salt has a value of less than 30. The present disclosure also relates to the uses of the disclosed cosmetic compositions for washing keratin fibers, for instance, colored hair, and for protecting the color of the keratin fibers from sunlight and/or repeated washing. | 2010-07-01 |
20100166694 | DIAGNOSTIC MARKERS OF WOUND INFECTION - The present invention relates to a method of determining the microbial bioburden in a wound (in particular a diabetic ulcer) in a test subject, the method comprising the step of measuring the level of a cytokine in a wound sample, wherein a cytokine level lower than a reference level indicates a significant microbial bioburden in the wound (or a cytokine level higher than a reference level indicates an insignificant microbial bioburden in the wound). The invention provides methods of diagnosis, prognosis and treatment of wound infection, and devices and kits for use in such methods. | 2010-07-01 |
20100166695 | Multivalent Heterobifunctional Polymers And Methods Of Their Use - Designed herein are multivalent heterobifunctional polymers for binding to a biological target exhibiting biological activity and to an effector template which can affect the biological activity of the biological target or detect the presence of the biological target. The polymers comprise a plurality of pre-arranged heterobifunctional ligands connected thereto, and each heterobifunctional ligand comprises a first functionality capable of binding to the biological target, and a second functionality capable of binding to the effector template. The heterobifunctional ligands are pre-arranged on the polymer so as to form a ternary complex between the polymer, the biological target and the effector template. The polymers, methods and compositions described herein provide an approach for the design and production of new therapeutic agents as well as agents useful in a variety of non-therapeutic applications. | 2010-07-01 |
20100166696 | AMIDO-AMINE DENDRIMER COMPOSITIONS - Amide compounds, amide polymers and compositions, including amide compounds and amide polymers, may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, the amide polymers may be amido-amine dendrimers that may be formed via a series of iterative reactions. | 2010-07-01 |
20100166697 | COMBINATION THERAPY USING TNF AND ALFA-GALACTOSYL CERAMIDE - The invention relates to the treatment of cancer. More specifically the invention shows that the anti-cancer activity in mammals can be augmented by administering to the mammalian host a combination of a synergistically effective amount of TNF and alfa-galactosylceramide. | 2010-07-01 |
20100166698 | NEW COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION - The present invention describes combinations of A | 2010-07-01 |
20100166699 | PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS - The invention provides a combination comprising an ancillary compound (e.g. one, two or more ancillary compounds) and a compound of the formula (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R | 2010-07-01 |
20100166700 | Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates and Their Preparation - The present invention relates to polymeric reagents and conjugates thereof, methods for synthesizing the polymeric reagents and conjugates, pharmaceutical compositions comprising the conjugates and methods of using the polymer conjugates including therapeutic methods where conjugates are administered to patients. | 2010-07-01 |
20100166701 | METHOD FOR TREATING RENAL CELL CARCINOMA USING GLYCOGENOLYSIS INHIBITORS - Renal cell carcinoma (RCC) exhibits unpredictable behavior, high recurrence rate, insensitivity to Positron-Emission Tomography (PET), and poor response to existing cancer treatments such as chemotherapy. Inhibition of glycogenolysis can restrict RCC tumor growth and increase its susceptibility to other treatments, in particular, those that compromise access to nutrient, such as anti-angiogenenic compounds. This can also increase uptake of glucose derivatives and thus increase sensitivity of PET. Reduction of glycogen stores within RCC through treatment with iron-salts can also reduce tumor growth rate through reducing activation of the hypoxia pathway. Thus, synergistic treatment of RCC with glycogenolysis inhibitors or inhibitors of glycogenosis, and/or in combination with anti-angiogenic compounds, can increase sensitivity of tumor detection, slow tumor formation and/or metastasis. | 2010-07-01 |
20100166702 | ALKYLATED INTERLEUKIN-18 AND RELATED COMPOSITIONS, KITS, AND METHODS OF MAKING AND USING SAME - Alkylated interleukin-18 (IL-18), compositions comprising alkylated IL-18, kits comprising such compositions, methods of alkylating IL-18, and methods of using compositions comprising alkylated IL-18. | 2010-07-01 |
20100166703 | USE OF IL-6/IL-6 CHIMERA IN HUNTINGTON'S DISEASE - The invention relates to the use of an IL-6R/IL-6 chimera, a mutein, isoform, fused protein, functional derivative, active fraction or circularly permutated derivative or a salt thereof, for the manufacture of a medicament for the treatment and/or prevention of Huntington's disease. | 2010-07-01 |
20100166704 | Methods and compositions for inhibition of viral replication - The present invention is directed to methods and compositions that are effective in the inhibition of viral replication. In particular, the methods and compositions are effective at interfering with the activity of host cell proteins required in viral replication. For example, an embodiment of the invention is directed to inhibition of flavivirus replication wherein the replication is affected by changing the normal interactions of the host cell protein TIAR or TIA-1. | 2010-07-01 |
20100166705 | Culturing circular ssDNA viruses for the production of vaccines - The present invention relates to the use of interferon in the in vitro cultivation of animal circular ssDNA virus such as Porcine Circovirus 2 or human TT virus in an animal cell line. Increased titres of animal circular ssDNA virus are obtained by addition of interferons or agents which ensure the production of endogenous interferons by said cell line and/or by the reduction of endosomal-lysosomal system acidification. | 2010-07-01 |
20100166706 | HCV NS-3 SERINE PROTEASE INHIBITORS - Methods drawn to peptidomimetic compounds which inhibit the NS3 protease of the hepatitis C virus (HCV), are described. The compounds have the formula (VI) where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site. | 2010-07-01 |
20100166707 | EXTRACELLULAR MATRIX/METASTASIS MODIFIER GENES FOR THE PREVENTION OR INHIBITION OF METASTASIS OR GROWTH OF TUMOR AND FOR CHARACTERIZATION OF TUMOR - Disclosed are methods involving the administration of an extracellular matrix (ECM)/metastasis modifier gene, e.g., Anakin, Necdin, CentaurinD3 (CentD3), Csf1r, Brd4, Pi16, and Luc7l, for the prevention or inhibition of metastasis or of tumor growth. Further disclosed are methods of characterizing a tumor or cancer in a subject comprising detecting (i) a single nucleotide polymorphism (SNP) in an Anakin gene or a Brd4 gene of the subject, (ii) an amino acid substitution in an Anakin protein in the subject, or (iii) a level of expression of an Anakin gene or a Brd4 gene in the subject. Methods of screening a compound for anti-cancer activity and use of a compound with anti-cancer activity for the preparation of a medicament to treat or prevent cancer in a subject are also disclosed. Also disclosed is a method of inhibiting Sipa-1 in a subject. | 2010-07-01 |
20100166708 | ANTIMICROBIAL AND ANTI-INFLAMMATORY THERAPIES AND COMPOSITIONS - The disclosure provides methods and compositions useful for treating microbial and viral infections. In certain aspects, the compositions and methods relate to the use of an effective amount of a delta-haemolysin and/or phenol soluble modulin-delta or functional variant thereof. In other aspects, the compositions and methods relate to the use of an effective amount of | 2010-07-01 |
20100166709 | Novel Bacteriophage and Antibacterial Composition Comprising the Same - The present invention relates to a novel bacteriophage, more particularly, a bacteriophage that has a specific bactericidal activity against one or more | 2010-07-01 |
20100166710 | Compositions and Methods for Inducing Neuronal Differentiation - The present invention provides compositions and methods for inducing neuronal cell differentiation. | 2010-07-01 |
20100166711 | METHOD FOR TREATING SKIN WOUNDS - The present invention relates to a method for treating a skin wound in an individual, comprising applying to the skin wound of the individual a therapeutically effective quantity of gingival fibroblasts. | 2010-07-01 |
20100166712 | BONE MARROW-DERIVED MESENCHYMAL STEM CELLS AS A SOURCE OF NEURAL PROGENITORS - Methods are provided for treating and/or reducing the severity of multiple sclerosis in a human, by administering autologous mesenchymal stem cell-derived neural precursors. Also described is an in vitro method for differentiating mesenchymal stem-cell derived neural precursor oligodengroglial and neuronal cell types. | 2010-07-01 |
20100166713 | EARLY MESODERM CELLS, A STABLE POPULATION OF MESENDODERM CELLS THAT HAS UTILITY FOR GENERATION OF ENDODERM AND MESODERM LINEAGES AND MULTIPOTENT MIGRATORY CELLS (MMC) - The present invention relates to the production of multipotent migratory cell (MMCs) which can be differentiated into mesoderm or endoderm lineages. Multipotent Migratory Cells (MMC) are stable and robust and can be passaged at least 20 times (perhaps indefinitely), can be recovered after freezing, reamplified and differentiated into multiple lineages. They are therefore storage stable. The method of producing these cells points to a way to generate a multipotent cell type (mesendoderm) from blastocycts for the generation of therapeutically useful cell types without going through a classical hESC state. The production of multipotent migratory cells, mesendoderm cells and mesoderm cells (Isl1+) is also described. | 2010-07-01 |
20100166714 | CARDIOVASCULAR STEM CELLS, METHODS FOR STEM CELL ISOLATION, AND USES THEREOF - The present invention relates to isolation of cardiovascular stem cells, and more particularly to cardiovascular stem cells positive for markers isll | 2010-07-01 |
20100166715 | T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR BONE MARROW RECOVERY - The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for providing improved bone marrow transplantation and in the treatment of other conditions wherein bone marrow depletion or suppression is involved. | 2010-07-01 |
20100166716 | Colony-forming unit cell of human chorion and method to obtain and use thereof - The present invention features colony-forming unit cells derived from the chorion of human placenta and describes compositions and methods for the uses of chorionic cells and their products for therapeutic purposes based upon production and release of multiple growth factors and cytokines by these cells stimulating tissue regeneration independent of engraftment, as well as differentiation into a specific cell type. | 2010-07-01 |
20100166717 | METHOD OF TREATING ISCHEMIC DISORDERS - A method of treating an ischemic disorders in a subject includes administering stromal cell derived factor-1 (SDF-1) to ischemic tissue of the subject in an amount effective to inhibit apoptosis of cells of the tissue. | 2010-07-01 |
20100166718 | LARGE SCALE PANCREATIC ISLET PURIFICATION - The present invention includes a method of isolating pancreatic islets by density centrifugation wherein the pancreatic islets are loaded in a solution comprising pancreatic islets with the density gradient and the islets are isolated by centrifuging the vessel wherein the pressure on the pancreatic islets is less than 50 Pa and wherein the pancreatic islets are isolated from the gradient, the improvement comprising creating a continuous density gradient in a vessel comprising at least 100 milliliters with a bend tube that reduces convection currents that disrupt the gradient. | 2010-07-01 |
20100166719 | Hair growth method - A method of enabling effective hair growth and furthermore, inducing hair growth closely similar to the natural hair state in the case of transplanting dermal papillae or cultured dermal papilla cells into the skin to regenerate the hair, characterized by comprising transplanting a composition containing the following components into an epidermis defect site: (a) dermal papillae or dermal papilla cells, (b) an epidermal tissue or epidermal cells and/or (c) a tissue constituting hair follicles or cells thereof. | 2010-07-01 |
20100166720 | GENERATION OF NEURONAL CELLS FROM PLURIPOTENT STEM CELLS - The invention relates to in vitro methods for differentiating mammalian pluripotent stem cells into cells displaying a neuronal phenotype, more particularly into cortical-type neurons including inter alia pyramidal neurons and cortical inhibitory interneurons. The invention further encompasses so-obtained neuronal cells and cell population, compositions comprising such, and further uses of said neuronal cells and cell population. | 2010-07-01 |
20100166721 | PROBOTIC COMPOSITIONS AND USES THEREOF - The present application relates to a probiotic composition comprising a probiotic bacteria. The composition is particularly useful as a food supplement for normalizing the gastro-intestinal flora. The probiotic bacteria present in the composition contain species of | 2010-07-01 |
20100166722 | T CELL THERAPIES - This invention provides a method of treating cancer or infection by administering T cells transfected with T cell receptors (TCRs) which in their soluble form have a half life for their interaction with their cognate peptide-MHC complex chosen to enhance the avidity of the T cells for target cells presenting that peptide MHC complex while maintaining the activation specificity of the T cells by that peptide-MHC complex. | 2010-07-01 |
20100166723 | GENES ENCODING NEMATODE TOXINS - Compositions and methods for conferring nematicidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions including a coding sequence for nematicidal polypeptides are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also include transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated nematicidal nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed. In particular, the present invention provides for isolated nucleic acid molecules including nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:4, 5, 8, 9, 13, 14, 47, 48, or 49, the nucleotide sequence set forth in SEQ ID NO:1, 2, 3, 6, 7, 10, 11, 12, 15, 45, or 46, as well as variants and fragments thereof. | 2010-07-01 |
20100166724 | USES OF THIOREDOXIN - The present invention relates to the use of thioredoxin as, inter alia, a cell growth stimulator, as well as a screen for agents that are useful in reducing or preventing thioredoxin-associated apoptosis inhibition and agents that are useful in inhibiting thioredoxin stimulated cell growth. | 2010-07-01 |
20100166725 | Human Cystathionine beta-Synthase Variants and Methods of Production Thereof - Human cystathionine β-synthase variants are disclosed, as well as a method to produce recombinant human cystathionine β-synthase and variants thereof. More particularly, the role of both the N-terminal and C-terminal regions of human CBS has been studied, and a variety of truncation mutants and modified CBS homologues are described. In addition, a method to express and purify recombinant human cystathionine β-synthase (CBS) and variants thereof which have only one or two additional amino acid residues at the N-terminus are described. | 2010-07-01 |
20100166726 | COMPOSITIONS FOR IMPROVING CELLULAR UPTAKE OF A CHEMOTHERAPEUTIC AGENT IN A CELL EXHIBITING MUCIN DEREGULATION - Methods and compositions that increase the cellular uptake of a chemotherapeutic agent are provided. Also provided are methods of increasing access to the cell surface by antibodies and ligands. The methods are useful in treating any mucinous carcinoma characterized by an increased expression and/or secretion of mucins. In addition, these methods provide an improvement in existing methods of chemotherapy. | 2010-07-01 |
20100166727 | S-Adenosylmethionine And Methylthioadensosine In Chemoprevention And Treatment Of Colon Polyps And Cancer - The present invention relates to S-adenosylmethionine (SAMe), methylthioadenosine (MTA) for the treatment of disease. More specifically, the invention relates to SAMe and MTA methods and compositions for the chemoprevention and treatment of colon polyps and cancer. | 2010-07-01 |
20100166728 | Novel Highly Functional Enzyme Having Modified Substrate-Specificity - The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having α-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired α-galactosidase activity by changing the structure of the active site of wild-type human α-N-acetylgalactosaminidase. | 2010-07-01 |
20100166729 | Modified factor VII polypeptides and uses thereof - Modified factor VII polypeptides and uses thereof are provided. Such modified FVII polypeptides include Factor VIIa and other forms of Factor VII. Among modified FVII polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics. | 2010-07-01 |
20100166730 | Liquid, Aqueous Pharmaceutical Composition of Factor VII Polypeptides - The present invention is directed to liquid, aqueous pharmaceutical compositions containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome, e.g., bleeding disorders, including those caused by clotting Factor deficiencies (e.g. haemophilia A, haemophilia B, coagulation Factor VII deficiency); by thrombocytopenia or von Willebrand's disease, or by clotting Factor inhibitors, and intra cerebral haemorrhage, or excessive bleeding from any cause. The preparations may also be administered to patients in association with surgery or other trauma or to patients receiving anticoagulant therapy. More particularly, the invention relates to liquid compositions stabilised against chemical and/or physical degradation. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; at least one metal-containing agent (iii), wherein said metal is selected from the group consisting of first transition series metals of oxidation state +II, except zinc, such as chromium, manganese, iron, cobalt, nickel, and copper; and a non-ionic surfactant (iv). | 2010-07-01 |
20100166731 | Methods and Compositions for Treating Cancer - The present invention relates to methods and compositions for treating cancers by reducing the expression or activity of one or more of the genes encoding protein kinases ATR, MAST2, MAP3K6, TBK1, ADRBK2, CDKL2, LATS2, STK32B, STK11, DDR13 PSKH2, and NEK8, and/or the encoded kinases. The invention also relates to methods and compositions for determining the responsiveness of a cancer patient to anti-cancer drugs based on the status of one or more of such kinases. The invention further relates to methods and compositions for screening compounds that can be used to modulate the expression/activity of these kinases. | 2010-07-01 |
20100166732 | SMALL STREPTOCOCCUS PYOGENES ANTIGENS AND THEIR USE - The present invention relates to a peptide consisting of one antigen of | 2010-07-01 |
20100166733 | MCP-1 SPLICE VARIANTS AND METHODS OF USING SAME - Novel MCP-1 splice variant polypeptides and polynucleotides encoding same are provided. Also provided are pharmaceutical compositions comprising the splice variant polypeptides and polynucleotides, vectors and host cells comprising same. The compositions of the present invention are useful to treat various MCP-1 related disorders as well as for diagnosing, determining predisposition and/or prognosis of various disorders. | 2010-07-01 |
20100166734 | ORAL DELIVERY OF POLYPEPTIDES - The present invention relates to the oral delivery of therapeutic polypeptides comprising one or more single variable domain(s). | 2010-07-01 |
20100166735 | METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS - The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment. | 2010-07-01 |
20100166736 | IMMUNOSTIMULATORY OLIGONUCLEOTIDE MULTIMERS - The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary. | 2010-07-01 |
20100166737 | P38Alpha as a Therapeutic Target in Bladder Carcinoma - The present invention concerns methods and compositions for treating bladder carcinoma by p38 inhibitors. | 2010-07-01 |
20100166738 | COMPOSITIONS AND METHODS FOR WT1 SPECIFIC IMMUNOTHERAPY - Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases. | 2010-07-01 |
20100166739 | Methods and Compositions for Diagnosing Urological Disorders - It has been discovered that cytokines, chemokines, and growth factors in urine are biomarkers indicative of urological disorders including interstitial cystitis/painful bladder syndrome and overactive bladder syndrome. Preferred chemokine biomarkers are CCL2, CCL4 (MIP-1β), CCL11, CXCL1 (GRO-α), sCD40L, IL-12p70/p40, IL-5, sIL-2Rα, IL-6, IL-10, IL-8, and EGF. The concentration of one or more of these chemokines in an urine sample can be used to assist in the diagnosis of urological disorders. Methods for evaluating the effectiveness of treatments for urological disorders and for assessing the severity of urological disorders are also provided. | 2010-07-01 |
20100166740 | Anti-OX40L antibodies - This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases. | 2010-07-01 |
20100166741 | ALTERED BR-3 BINDING POLYPEPTIDES - The present invention relates to novel BR3 binding antibodies having altered Fc effector function and/or having a mature core carbohydrate structure in the Fc region which lacks fiicose. The present invention also relates to the use of those BR3 binding antibodies and polypeptides in, e.g., methods of treatment, screening methods, diagnostic methods, assays and protein purification methods. | 2010-07-01 |
20100166742 | METHOD FOR PROMOTING IMMUNOTHERAPIES - The present invention relates to an ex vivo method for increasing the effectiveness of antibodies and Fcγ receptor-binding active ingredients, comprising the steps of: a) preparing a blood sample of a patient; b) subjecting the blood sample to an immunoapheresis; c) administering a therapeutically effective antibody or an Fcγ receptor-binding active ingredient to the patient. | 2010-07-01 |
20100166743 | METHOD OF DETECTING OCULAR DISEASES AND PATHOLOGIC CONDITIONS AND TREATMENT OF SAME - Methods of detecting and treating diseases and pathological conditions of the eye are disclosed. In particular a genetic variant of the HtrA1 gene is correlated to age related macular degeneration (AMD). In addition, biologically active agents capable of inhibiting HtrA1 activity are provided, and methods of treating diseases and pathological conditions of the eye are additionally disclosed. | 2010-07-01 |
20100166744 | USE OF ANTI-EGFR ANTIBODIES IN TREATMENT OF EGFR MUTANT MEDIATED DISEASE - The present invention relates to the treatment of EGFR-mediated disease, particularly cancer, which is resistant to tyrosine kinase inhibitor therapies. Methods for treatment of cancer and reduction of tumor growth in individuals with secondary EGFR mutations, particularly tyrosine kinase domain mutations, resistant to standard therapy are provided. The invention provides methods for the treatment of tyrosine kinase inhibitor resistant cancers with anti-EGFR antibodies. Methods for treatment of recurrent lung cancer, including non-small cell lung carcinoma which is resistant to tyrosine kinase inhibitors, with the antibody anti-EGFR mAb806 are described. | 2010-07-01 |
20100166745 | TRANSFERRIN RECEPTOR ANTIBODIES - The invention provides further characterization of the disease and cancer-associated antigen, transferrin receptor. The invention also provides a novel family of antibodies that bind to the transferrin receptor, methods of diagnosing and treating various human cancers and diseases that express transferrin receptor. | 2010-07-01 |
20100166746 | HIGH POTENCY RECOMBINANT ANTIBODIES, METHODS FOR PRODUCING THEM AND USE IN CANCER THERAPY - The present invention contemplates improved recombinant anti-tumor antibodies having faster Kon and faster Koff rates, resulting in a uniform tumor penetrance, as compared to the same recombinant anti-tumor antibody without said faster Kon and faster Koff rates, and methods of improving the same. | 2010-07-01 |
20100166747 | METHODS AND COMPOSITIONS FOR TREATING TUMOR DISEASES - The present invention provides, in part, methods for treating a tumor in a human subject comprising inhibiting IGF-1 receptor signaling, methods of determining whether a tumor is more or less likely to respond to such treatment, and compositions for practicing such methods. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions. | 2010-07-01 |
20100166748 | C5 Antigens and Uses Thereof - The present invention pertains to the use of a complement inhibitor in methods of treatment of ocular disorders and the use of a complement inhibitor in the manufacture of a medicament in the treatment of an ocular disorder. | 2010-07-01 |
20100166749 | Polypeptide variants with altered effector function - The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof. | 2010-07-01 |
20100166750 | Indications for Anti-IL-1 Beta Therapy - This invention relates to a novel use of IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1β ligand-IL-1 receptor interaction, IL-1β antibodies or IL-1 receptor antibodies, e.g. IL-1β binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1β binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1β ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans. | 2010-07-01 |
20100166751 | CANCER THERAPY USING WHOLE GLUCAN PARTICLES AND ANTIBODIES - The present invention relates to methods of using whole glucan particles and complement activating antibodies for antitumor therapy. Whole glucan particles enhance the tumoricidal activity of the innate immune system by binding to the C3 complement protein receptor CR3. This binding enhances innate immune system cytotoxicity, as well as stimulating the release of activating cytokines. | 2010-07-01 |
20100166752 | Anti A Beta Antibody Formulation - The present invention provides formulations for maintaining the stability of Aβ binding polypeptides, for example, Aβ antibodies. Exemplary formulations include a tonicity agent such as mannitol and a buffering agent or amino acid such as histidine. Other exemplary formulations include an antioxidant in a sufficient amount as to inhibit by-product formation, for example, the formation of high molecular weight polypeptide aggregates, low molecular weight polypeptide degradation fragments, and mixtures thereof. The formulations of the invention optionally comprise a tonicity agent, such as mannitol, and a buffering agent or amino acid such as histidine. The formulations are suitable for several different routes of administration. | 2010-07-01 |
20100166753 | HUMANIZED MONOCLONAL ANTIBODIES THAT PROTECT AGAINST SHIGA TOXIN INDUCED DISEASE - The present invention describes the preparation and use of biologically and immunologically active humanized monoclonal antibodies to Shiga toxin, a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how these humanized antibodies may be used in the treatment or prevention of Shiga toxin induced diseases. One aspect of the invention is the humanized monoclonal antibody which binds Shiga toxin where the constant regions are IgG1-kappa and the variable regions are murine in origin. Yet another aspect of the invention is expression vectors and host cells transformed with such vectors which express the humanized monoclonal antibodies of the present invention. | 2010-07-01 |
20100166754 | Methods and Compositions For Treating Autoimmune Diseases or Conditions - The present invention relates to methods of treating immune disorders, particularly autoimmune and inflammatory disorders such as rheumatoid arthritis, and methods of producing antibodies for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies that specifically bind to NKG2D receptors present on the surface of cells underlying the disorders. | 2010-07-01 |
20100166755 | ANTI-EGFR ANTIBODIES - The present invention encompasses EGFR specific monoclonal antibodies, or antigen-binding portions thereof. These antibodies, or antigen-binding portions thereof, have high affinity for EGFR, inhibit the activation of EGFR, and are useful for the treatment of EGFR mediated cancers. | 2010-07-01 |
20100166756 | METHOD FOR TREATING AN AUTOIMMUNE DISEASE USING A SOLUBLE CTLA4 MOLECULE AND A DMARD OR NSAID - The present invention relates to compositions and methods for treating immune system diseases such as rheumatic disease, by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands, alone, or in conjunction with other agents including Disease Modifying Anti-Rheumatic Drugs (DMARDs). | 2010-07-01 |
20100166757 | ANTIBODIES AGAINST MONOCYTE CHEMOTACTIC PROTEINS - The invention provides antibodies that bind to a plurality of β-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same. | 2010-07-01 |
20100166758 | NOVEL ANTIBODY MOLECULES AND NUCLEIC ACIDS - An scFv peptide comprising a V | 2010-07-01 |
20100166759 | Metallothionein-Derived Peptide Fragments - The present invention relates to neural cell survival, differentiation and proliferation promoting peptide fragments derived from metallothioneins (MT), pharmaceutical compositions comprising said peptide fragments and uses thereof for treatment of diseases and conditions where the effects of stimulating neural cell proliferation, differentiation and/or survival, and/or stimulating neural plasticity associated with learning and memory are beneficial for treatment. | 2010-07-01 |